关于<\/b>EMPEROR<\/b>心力衰竭研究<\/b>[15],[16] <\/p> \n
EMPEROR（采用恩格列净治疗慢性心衰患者的结局试验）慢性心衰研究包括两项III期、随机、双盲试验，针对射血分数降低与射血分数保留的成人慢性心衰患者（均包括伴与不伴糖尿病的患者），在接受标准治疗的基础上，研究每日一次恩格列净与安慰剂相比的疗效与安全性：<\/p> \n
关于<\/b>EMPOWER<\/b>项目<\/b><\/p> \n
联盟开发了EMPOWER项目，旨在探索恩格列净对一系列心脏-肾脏-代谢疾病的主要临床心血管和肾脏结局的影响。心肾代谢疾病是全球死亡的主要原因，每年导致的死亡病例高达2000万。[17]通过EMPOWER项目，勃林格殷格翰和礼来正在努力增加对这些相关系统的认知，并开发可提供综合、多器官获益的治疗。EMPOWER由9项临床试验和两项真实世界研究组成，EMPEROR强化了联盟对改善心脏-肾脏-代谢疾病患者临床治疗结局的长期承诺。临床研究全球入组超过400，000位成人患者，EMPOWER是迄今为止针对SGLT2抑制剂开展的最广泛和最全面的临床项目之一。<\/p> \n
关于心力衰竭<\/b><\/p> \n
心力衰竭是一种进行性加重、导致虚弱并可能危及生命的疾病，当心脏不能供应足够的血液循环以满足身体对含氧血液的需求或需要增加血容量导致肺部和外周组织液体积聚（充血）时发生。[18],<\/sup>[19]心力衰竭是一种常见的疾病，累及全球6000万人，[3,4] 其发病率预计会随着人口老龄化而增加。心力衰竭在糖尿病患者中非常普遍 ，[20] 然而大约一半的心力衰竭患者不伴有糖尿病。[21]<\/p> \n 心力衰竭有不同的类型。患者可以伴有左侧射血分数降低或保留的心力衰竭。射血分数是测量每次左心室收缩时泵出的血液百分比。[22]当心脏舒张时，心室重新充满血液。<\/p> \n 心力衰竭患者经常会出现呼吸困难和疲劳，这会严重影响他们的生活质量。[23]患有心力衰竭的患者通常也有肾功能受损，这会对预后产生显著的负面影响。[24]<\/p> \n 关于心脏<\/b>-<\/b>肾脏<\/b>-<\/b>代谢疾病<\/b> 勃林格殷格翰和礼来希望能改变心脏-肾脏-代谢疾病患者的治疗方式，这是一组相互关联的疾病，影响全球超过10亿人，是死亡的主要原因。[4,17]<\/p> \n 心血管、肾脏和代谢系统相互关联，在疾病谱中具有许多相同的风险因素和病理途径。一个系统的功能障碍可能会加速其它系统的发病，从而导致相关疾病的发展，如2型糖尿病、心血管疾病、心力衰竭和肾脏疾病等相互关联的疾病，进而导致心血管死亡风险增加。相反，一个系统的改善可以在其它系统中产生积极的影响。[25],[26],[27]<\/p> \n 通过我们的研究和治疗，我们的目标是支持患者的健康，恢复相互关联的心脏-肾脏-代谢系统之间的平衡，并降低他们发生严重并发症的风险。作为对那些健康受到心脏-肾脏-代谢疾病危害患者承诺的一部分，我们将继续研究多学科治疗方案，并将我们的资源集中在填补治疗空白上。<\/p> \n 关于恩格列净<\/b><\/p> \n 恩格列净（商品名为欧唐静® ）是一种口服、每日一次、高选择性钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，也是首个在诸多国家的说明书中包含降低心血管死亡风险数据的2型糖尿病药物。[9,10,11]<\/p> \n 关于勃林格殷格翰和礼来<\/b><\/p> \n 2011年1月，勃林格殷格翰公司和礼来制药宣布达成合作协议，合作内容包括数类降糖药物的多个品种。基于不同的市场，双方将选择共同推广或单独推广各自为此项合作所提供的药物。这项合作整合了两大专注于患者需求的全球领先制药公司的实力，通过携手合作，两家公司承诺致力于帮助糖尿病患者，并探索解决患者未满足的医疗需求。评估恩格列净对心力衰竭或慢性肾脏疾病患者影响的临床试验已经启动。<\/p> \n 关于勃林格殷格翰<\/b><\/p> \n 勃林格殷格翰致力于研究突破性疗法，旨在改善人类和动物的健康。作为一家研发驱动的全球领先生物制药企业，公司在医疗需求高度未得到满足的领域通过创新展现价值。自1885年成立以来，勃林格殷格翰始终是一家独立的家族企业，从长远来看这一点将不会改变。在人用药品、动物保健和生物制药合同生产三大业务领域，全球有约5.2万名员工服务逾130个地区。更多详情，请访问：www.boehringer-ingelheim.com<\/a><\/p> \n 关于礼来公司<\/b> 作为全球医疗健康产业领导者，礼来致力于以创新回报患者、以关爱呵护生命。创立一百四十余年来，礼来始终奉行着以最新技术为患者提供最优质药品的理念，这与公司创始人礼来上校的承诺一脉相承。今天，礼来仍然执着于这一使命，并据此开展各项工作。世界各国的礼来人不仅潜心研发挽救生命的药品、积极帮助患者更好地认识和管理疾病，还通过慈善公益活动全心回馈社会。欲了解更多关于礼来制药的信息，请登录 http:\/\/www.lilly.com<\/a> 和https:\/\/newsroom.lilly.com\/social-channels<\/a>.<\/p> \n CONTACTS:<\/b><\/p> \n Stefanie Molkenthin<\/span><\/b> Anna Bergmann<\/span> References<\/b><\/p> \n [1] Anker S, Butler J, Filippatos G, et al<\/i>. Empagliflozin in Heart Failure With a Preserved Ejection Fraction. N Engl J Med<\/i>. 2021;[insert]. <\/p> \n [2] Anker S. EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without diabetes. Presented on 27 August 2021<\/span> at the European Society of Cardiology (ESC) Congress 2021 – The Digital Experience.<\/p> \n [3] Andersen MJ, Borlaug BA. Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep<\/i>. 2014;16(7):501.<\/p> \n [4] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet.<\/i> 2018;392(10159):1789–858.<\/p> \n [5] Butler J, Fonarow G, Zile M, et al<\/i>. Developing therapies for heart failure with preserved ejection fraction: Current State and Future Directions. JACC Heart Fail<\/i>. 2014 Apr;2(2):97–112.<\/p> \n [6] Shah SJ, Borlaug B, Kitzman D, et al<\/i>. Research priorities for heart failure with preserved ejection fraction. Circulation<\/i>. 2020;141:1001–26.<\/p> \n [7] Boehringer Ingelheim. Data on file.<\/p> \n [8] Packer M, Anker SD, Butler J, et al<\/i>. Cardiac and Renal Outcomes With Empagliflozin in Heart Failure With a Reduced Ejection Fraction. N Engl J Med.<\/i> 2020;383:1413–24.<\/p> \n [9] Jardiance® (empagliflozin) tablets. European Product Information, approved April 2020<\/span>. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jardiance-epar-product-information_en.pdf<\/a>. Accessed August 2021<\/span>.<\/p> \n [10] Jardiance®<\/sup> (empagliflozin) tablets, U.S. Prescribing Information. Available at: http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf<\/a>. Accessed: August 2021<\/span>.<\/p> \n [11] Jardiance®<\/sup> (Full Prescribing Information). Mexico<\/span>; Boehringer Ingelheim Pharmaceuticals, Inc; 2017.<\/p> \n [12] [PDUFA announcement].<\/p> \n [13] ClinicalTrials.gov. EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509674<\/a>. Accessed: August 2021<\/span>.<\/p> \n [14] ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03594110<\/a>. Accessed: August 2021<\/span>.<\/p> \n [15] ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057977<\/a>. Accessed: August 2021<\/span>.<\/p> \n [16] ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951<\/a>. Accessed: August 2021<\/span>.<\/p> \n [17] GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet<\/i>. 2016; 388(10053):1459–544.<\/p> \n [18] American Heart Association. What is Heart Failure? Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure<\/a>. Accessed: August 2021<\/span>.<\/p> \n [19] American Heart Association. Types of Heart Failure. Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/types-of-heart-failure<\/a>. Accessed: August 2021<\/span>.<\/p> \n [20] Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. <\/i>2019;124(1):121–41.<\/p> \n [21] Dunlay SM, Givertz MM, Aguilar D, et al.<\/i> Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America. Circulation.<\/i> 2019;140:e294–e324.<\/p> \n \n
<\/p> \n
<\/p> \n
Product Communication Manager
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com<\/a>
Phone: +49 (6132) 77 172 209<\/p> \n
<\/b>Global Business Communications
Eli Lilly and Company
Email: anna.bergmann@lilly.com<\/a>
Phone: +1 317 864 3143<\/p> \n